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Introduction: Sickle Cell Disease (SCD), an inherited disorder of the red blood cells, is a major 
public health problem. India, with a population of 1.2 billion individuals, is estimated to be home 
to over 50% of the world’s patients with SCD. While SCD is common among all ethnic groups 
in India, high prevalence has been reported in three socio-economically disadvantaged ethnic 
categories: the Scheduled Castes (SC), the Scheduled Tribes (ST), and Other Backward Class 
(OBC) groups.  
Both the prevalence of the βs gene and the clinical phenotype of SCD have not been well 
described in these three population groups.  
Objective: Our objective was two-fold: to determine the prevalence of the βs gene and to 
describe the clinical phenotype of SCD in the district of Nagpur, Maharashtra located in Central 
India.  
Method: To determine the prevalence of the βs gene, community screening of target populations 
was conducted over an eight-year time span. To determine the clinical phenotype of SCD, a 
cohort of 726 patients was followed over a four and half year time period during which all 
clinical events presented to the hospital were recorded.  
Results 
Population Screening: Community wide screening of 35,636 individuals identified 
5,437 individuals with sickle cell trait and 1,010 with SCD. The trait prevalence was 13%, 12%, 
and 3.4% for the SC, ST, and OBC groups respectively.   
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Clinical Phenotype: A total of 726 patients were followed in the comprehensive clinic 
over a four and a half year time period. Painful crisis and fever were the most common initial 
presentations and the leading causes of hospitalizations. These rates were also higher when 
compared to the published data from the Cooperative Study of Sickle Cell Disease. 
Implications for Public Health: The population screening program uncovered previously 
undiagnosed cases, and provided detailed information for population based disease counseling, 
prevention programs and comprehensive care programs. Additionally, we present evidence 
suggesting that SCD may not have milder manifestations in India and underscore the need for 
detailed studies of phenotype that can form the basis of public health interventions and 
mechanistic studies of genetic modifiers of clinical phenotype.  
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1.0  INTRODUCTION 
Sickle cell disease (SCD), the most common single-gene blood disorder (hemoglobinopathy) in 
the world, represents a significant public health problem in India. In India, SCD is highly 
prevalent in the Western, Central, and Eastern regions and in pockets of the South in the states of 
Maharashtra, Madhya Pradesh, Orissa, Andhra Pradesh, Gujarat, Chattisgarh, Tamil Nadu, and 
Kerala. [1-9] SCD is an inherited disorder of the red blood characterized by vaso-occlusive pain 
crises, risk for pneumococcal infections, acute chest syndrome, stroke and organ failure and is 
associated with substantial morbidity and premature mortality. [6]  
With a population of over 1.2 billion individuals, it is estimated that India is home to over 
50% of the world’s SCD patients. [8] While sickle cell is prevalent in many ethnic groups, the 
highest prevalence appears to be in three particular socio-economically disadvantaged 
communities, identified as the Scheduled Castes (SC), Scheduled Tribes (ST), and Other 
Backward Classes (OBC). [8] Each of these categories consists of several different large ethnic 
groups that have practiced endogamy, or the practice of marrying within a specific group, for 
millennia and thus represent genetic isolates. In order to be useful for the purposes of planning 
for genetic counseling services, control programs, clinical service provision or genetic 
epidemiological studies, screening should generate prevalence estimates of the βs gene in each 
ethnic group. The prevalence of the βs gene has been well described in the ST population; 
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however, such precise estimates are not available for the OBC population or the SC population. 
Together these three groups comprise over 75% of the Indian population. [5, 6, 10, 11] 
Similarly, the clinical phenotype of SCD in the Indian population has been described 
mainly in the ST group and not in the SC or OBC groups. Previous studies describe the milder 
manifestations of SCD in the Indian population compared to that observed in the African and 
Caribbean populations. [12] Proposed epistatic factors or modifiers contributing to the 
amelioration of clinical phenotype include the high prevalence of the Arab-Indian β globin 
haplotype, high Hemoglobin F levels, presence of Xmn1 polymorphic site, and high frequency of 
alpha Thalassemia in certain population groups. [13-20] However, there has been a lack of 
detailed phenotypic studies of SCD in various populations in India, and such studies are 
important not only to understand the clinical and public health impact of the disease in the region 
but are also essential prior to undertaking mechanistic studies of molecular mechanisms 
modulating disease severity. [15-17] The Cooperative Study of Sickle Cell Disease conducted in 
the United States over a 20 year time period is the largest study prospective study of natural 
history of sickle cell disease conducted to date and has yielded rich data on the clinical course 
and natural history of disease and has contributed to a variety of mechanistic studies.[13]   
Central India, which is one of the high prevalence regions for the βs gene, has a 
prevalence rate of 9.4-22.2% for this mutation in various communities. [3, 7] The state of 
Maharashtra in Central India has a population of 112.3 million of which the SC and ST comprise 
10.2% and 8.9% of the population respectively.[11] Additionally, the OBC population comprises 
52% of the population.  
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The purpose of our study was two-fold: to determine the prevalence of the βs gene and to 
describe the clinical phenotype SCD in the district of Nagpur, Maharashtra, located in Central 
India. 
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2.0  BACKGROUND & SIGNIFICANCE  
Sickle cell disease or sickle cell anemia is a hereditary genetic disease that is characterized by the 
presence of abnormal crescent-shaped red blood cells.[21] While the symptoms related to SCD 
were known by various names throughout Africa for centuries, it was not until 1910, when James 
Herrick, a physician, noted the presence of a “peculiar elongated sickle shaped red blood cells” 
in the blood of an anemic African medical student that the Western world and the scientific 
community became aware of the disease. [21] A few years after Dr. Herrick’s report, Dr. Emmel 
noted that a patient and her father, both asymptomatic, had sickled blood cells.[22] Furthermore, 
three of the patient’s siblings had died from severe anemia. These observations made by Dr. 
Emmel were the first to suggest a genetic basis for SCD, although the specific pattern of 
inheritance was not delineated until the early 1920s. [22] In 1949, Linus Pauling et al. were the 
first to suggest that the cause of SCD was the result of defective hemoglobin molecules. [23] 
Hemoglobin (Hb) molecules are a set of proteins formed by pairing of two alpha (α) and 
two beta (β) globin polypeptide chains into a tetromeric unit. [24-27] This unit, the α2β2 
molecule, forms the major adult hemoglobin responsible for the transport of oxygen from the 
lungs to tissues. The α-globin gene is located on chromosome 16 and encodes the adult α-globin 
and the ζ-globin chain, which is the embryonic form of α-globin.[25] The β-globin gene is 
located on chromosome 11 and encodes four different globin molecules: embryonic ε-globin, 
fetal γ-globin, adult δ-globin and adult β-globin, all expressed differently during specific times of 
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development. [25, 27] Figure 1 illustrates the timeline of the expression of the human globin 
genes from early stages of fetal development to the changes that occur at birth and the first year 
of life. [25] 
 
Figure 1. The timeline of human globin gene expression Adapted from Schechter[25] 
 Hundreds of different structural variants of hemoglobin have been reported in the 
literature. The most common clinically significant structural variants are HbA, HbA2, Hb S, 
HbC, HbF, HbD, and Hb O, shown in Table 1. [26] SCD is used to describe a wide range of 
hemoglobinopathies that are characterized by Hb S in the presence of another variant beta globin 
chain. The majority of SCD cases are composed of four primary subtypes: SS, SC, S βo, and 
Sβ+.[26] 
Table 1. Different Structural Variants of Hemoglobin 
Hb A α2β2 
Hb A2 α2δ 2 
Hb S Glutamic acid (GAG)  valine (GTG) at 
position β6  
Hb C Glutamic acid (GAG)  lysine (AAG) at 
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position β6 
Hb F α2γ 2 
Hb D Los Angeles or Punjab Glutamic acid (GAG)  glutamine (CAG) at 
position β121 
Hb O Arab Glutamic acid (GAG)  lysine (AAG) at 
position β121 
Hb E Glutamic acid (GAG)  lysine (AAG) at 
position β26 
βo Thalassemia Absence of Hb A due to inability to produce 
normal β-chain 
β + Thalassemia Reduced amount of β-chain production leads to 
variable amount of Hb A.  
2.1 SICKLE CELL DISEASE 
Sickle cell disease is an autosomal recessive genetic blood disease that affects individuals of 
African, Mediterranean, Indian, Middle-Eastern, Caribbean, South and Central American 
ancestry. SCD is characterized by the presence of HbS, caused by a single point mutation 
involving GAG     GTG transversion at codon 6 of the β-globin gene.[24, 26-28] This results in 
an amino acid substitution at position 6 in the β-globin chain from glutamic acid to valine on the 
surface of the hemoglobin molecule. This amino acid change results in a change in the 
characteristics of the deoxygenated HS which causes HbS to become less soluble compared to 
HbA, and when HbS becomes deoxygenated, polymerization of HbS occurs. [24, 26] This 
polymerization of HbS results in the formation of elongated rigid fibers that damage the 
cytoskeleton of the red blood cell, causing the shape of the cell to change from the smooth, 
doughnut-shape to the hallmark sickle-shape. [28-31] (Figure 2) As the red blood cell becomes 
re-oxygenated the HbS fibers dissociate and revert back to the doughnut-shape. However, as the 
red blood cell passes through the circulatory system repeatedly, it becomes increasingly more 
Table 1 continued 
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damaged and the cycles of sickling and unsickling lower the life span of the red blood cell from 
120 days to less than 20 days. [24, 26, 29-31] 
   
 
 
 
Figure 2. Hallmark Sickle-Shaped red blood cell shape (L) versus normal red blood cell shape(R)  
These sickled cells then form homotypic aggregations and heterotypic adhesion to 
endothelial cells and white blood cells and contribute to the obstruction of blood flow and vaso-
occlusion that are hallmark clinical presentations of SCD. [29] This obstruction also results in a 
lack of adequate blood supply to organs and tissues resulting in damage.  The pathophysiology of 
SCD is illustrated in Figure 3.[23] 
 
Figure 3. Pathophysiology of SCD  
 (a) Point mutation in sickle cell disease. (b) Polymerization of hemoglobin S (HbS) under-deoxygenation. 
(c) Red blood cell shape change in response to HbS polymerization. (d) Reticulocyte adhered to endothelium 
initiates vaso-occlusion by trapping irreversibly sickled cells and forming aggregates with white blood cells.[23] 
 8 
2.2 INHERITANCE 
SCD is inherited in an autosomal recessive pattern, which occurs when an individual inherits one 
abnormal hemoglobin gene from each parent. If an individual inherits one abnormal hemoglobin 
gene and one normal gene then he/she is considered to have sickle cell trait or a carrier for SCD. 
If both parents are carriers for SCD then there is a 25% or 1 in 4 chance in each pregnancy of 
having a child who will inherit both abnormal hemoglobin genes and present with SCD. [32, 33]  
2.3 CLINICAL SYMPTOMS 
Clinical symptoms or manifestations of SCD include hemolysis, anemia, pain crisis, infection, 
acute chest syndrome swelling and vascular occlusion potentially leading to ischemic attacks and 
organ damage. [34, 35]  
2.3.1 Blood 
Acute painful crises are the most common type of vaso-occlusive event that occurs in SCD and is 
the most common reason for admission to hospital for both adults and children. [36] The exact 
mechanism leading to a pain episode is still unclear although it is thought to be a continuous 
cycle in which vaso-occlusion results in tissue ischemia and damage, leading to a secondary 
inflammatory response that triggers the release of norepinephrine which ultimately leads to 
further tissue ischemia. [37] The severity, frequency, location and duration of pain crises are 
variable among patients and can be triggered by a number of different events or factors 
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including: extreme temperatures or changes in humidity, dehydration, stress, alcohol 
consumption, infection, menses, obstructive sleep apnea and cardiac or pulmonary impairments. 
[38-47] 
The decreased lifespan of the red blood cells (120 days to <20 days) is also responsible 
for patients to experience chronic anemia with varying degrees of severity. [38-47]  
2.3.2 Spleen 
An organ to be affected early in SCD is the spleen, which is commonly enlarged during the first 
decade of life and can undergo progressive atrophy due to repeated attacks of vaso-occlusion and 
infarction. [48] Individuals with SCD may experience a wide range of splenic involvement from 
minimal change, splenomegaly, asplenia, and splenic sequestration crisis tor hypersplenism. 
Splenic complications of SCD are associated with an increased morbidity and in some cases lead 
to death. [48] 
Splenic sequestration crisis results from the rapid sequestration of red blood cells in the 
spleen; it is a serious complication of SCD and considered to be the second leading cause of 
death after infection in the first decade of life. [48] Splenic sequestration is characterized by 
sudden onset of anemia, splenomegaly, evidence of active bone marrow and a decrease in spleen 
size after blood transfusion. Hypersplenism is defined as splenomegaly with anemia, 
thrombocytopenia, neutropenia either singly or in combination.[48] 
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2.3.3 Neurological 
SCD is one of the most common causes of cerebrovascular accidents (stroke) in children. While 
the exact pathophysiology of stroke remains uncertain, contributory factors include anemia, 
leukocytosis, hypoxemia, abnormal rheology causing endothelial damage, and functional nitric 
oxide deficiency associated with hemolysis. [27, 28, 36] Approximately 11% of patients will 
have a stroke by 20 years of age, and once a stroke has occurred, the recurrence risk is greater 
than 60%. [36, 49] 
2.3.4 Pulmonary 
Individuals with SCD may present with a variety of chronic manifestations including restrictive 
and obstructive lung disease, hypoxemia, pulmonary hypertension, airway hyper-reactivity, 
asthma, or acute chest syndrome. [27, 28, 50-52] Acute chest syndrome is the second most 
common cause of hospitalizations in SCD and occurs in 40% of patients. [27, 32, 36, 53] Acute 
chest syndrome is characterized by infiltration of the pulmonary vasculature with sickled red 
blood cells. Individuals experiencing acute chest syndrome may present with chest pain, 
tachypnea, fever, rales and rhonchi, leukocytosis, or lobar consolidations. [28, 54] 
2.3.5 Infection 
A major cause of morbidity and mortality in patients with sickle cell disease is infection. The 
most common infection causing organism is pneumococcus, and children under the age of three 
are particularly at an increased risk of infection. [24, 28] Ideally, penicillin prophylaxis is 
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initiated in the first few months of life as a form of treatment for SCD patients to prevent 
pneumococcal infection. [24, 28] Impaired splenic functioning, tissue ischemia, micronutrient 
deficiencies and defects in the activation of the complement pathway are believed to result in an 
increased risk of bacterial and viral infections. [36, 53] Streptococcus, influenza, salmonella, 
malaria, hepatitis, parvovirus and chlamydophila are other commonly reported infection in 
patients with SCD. [27, 28, 36, 53] 
2.3.6 Renal/Kidney 
One of the main renal complications seen in individuals with sickle cell disease is occlusion of 
the vasarecta capillaries in the renal medulla, leading to a change in the delivery of oxygen to the 
kidney, which in turn leads to ischemic damage. [24, 55] Other renal manifestations include 
hematuria, proteinuria and hypertension, renal infarction, papillary necrosis, renal colic, 
nephrogenic diabetes insipidus leading to polyuria, focal segmental glomerulosclerosis leading to 
end-stage renal disease and renal medullary carcinoma.[27, 28, 55] 
2.3.7 Ophthalmologic 
The blood vessels of the eye may be damaged in patients with SCD due to the physiological 
changes that occur in the red blood cells. [28, 56] These changes result in the formation of new 
blood vessels that are weaker and more susceptible to rupture. [28, 56] Depending on the tissue 
that is involved and the location of the damage, an individual’s vision may or may not be 
affected. [24, 28] In patients whose vision is affected the primary complications are proliferative 
retinopathy, retinal artery occlusion, or retinal detachment and hemorrhage. [57, 58]  
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2.3.8 Growth and Development 
The birth weight and length of infants with SCD are typically along the normal growth curve. 
However, as time progresses, the mean height and weight of individuals with SCD may drop 
below the 50th percentile, specifically around the age of two. [24, 28] And as the children 
become older, the growth deficits can become more pronounced. [24, 28] Both females and 
males may experience delays in sexual maturation and progression through the Tanner stages of 
development. [24, 28] Females may also experience delays in the onset of menarche while males 
may experience lower levels of testosterone, dihydrotestosterone, and androsteneion. [24, 28, 47]  
2.3.9 Bone 
Due to a limited blood supply to some regions of the body, SCD patients may experience bone 
and joint concerns. Bone complications include bone infarction or osteomyelitis. Osteomyelitis, 
an acute or chronic bone infection, is most often caused by salmonella. [24, 28] Bone infarctions 
include dactylitis, commonly known as hand-foot syndrome, which is characterized by painful 
swelling of the hands and feet that generally resolves within a week. [24, 27, 28, 33, 59, 60] 
Hand-foot syndrome is typically the first clinical manifestation seen in infants with sickle cell 
disease between the ages of six months and two years. [24, 28] 
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3.0  SPECIFIC AIMS 
This study has two specific aims: 
1) To describe the prevalence of the βs gene in the scheduled caste, scheduled tribe, and 
other backward class population in the district of Nagpur, Maharashtra in Central 
India.  
2) To examine the clinical events in a large cohort of patients with SCD, followed in a 
single center in Nagpur, Maharashtra in Central India to determine the clinical 
phenotype of SCD in this population.  
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4.0  METHODS 
4.1 POPULATION SCREENING 
The Regional Hemoglobinopathy Detection and Management Center (RHDMC) at the Indira 
Gandhi Medical College located in Nagpur, Maharashtra, has mass community-based and 
hospital-based screening, management and counseling for sickle cell disease. The institution 
serves as a referral center with a population of over 10 million individuals in the region and 
where the high βs prevalence communities of Scheduled Castes, Scheduled Tribes and Other 
Backward Classes comprise 55% of the population. 
The present study was performed over a span of eight years (2003-2012) and includes the 
screening of target populations in all age groups (newborns, school age children, young adults, 
and pregnant mothers) as well as screening in hospital for individuals considered to be at high 
risk of carrying the βs gene. Informed consent was obtained from all adults and parents of 
children once the individuals were educated on the reasoning behind screening. The screening 
teams were comprised of a clinician, multiple lab technicians and counselors, and volunteers 
from the villages surrounding the screening camp. Screening camps were conducted in villages 
wihin a 300km radius around Nagpur that included the areas of Durg, Raipur, Chandrapur, 
Bhandara, Gondia, Gadhchiroli, Amravati, and Wardha (Figure 4).  
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Figure 4. Districts in the State of Maharashtra, India. The circle represents the areas in which 
community screening camps were conducted. [61] 
4.1.1 Screening Procedure 
Finger stick samples were taken by the technologists into glass tubes containing reagents (hyper-
osmolar phosphate buffer, saponin, reducing agent) for the solubility test, and all positive 
subjects had 5 ml of venous blood taken into tubes containing EDTA, which were stored in a 
cooler until return to the base laboratory. Alkaline hemoglobin electrophoresis on agar gel in 
Tris–EDTA–borate buffer at pH 8.6 was conducted on all solubility positive samples along with 
known controls for all individuals at the screening camps. [5] High performance liquid 
chromatography testing was performed on all samples testing positive for HbSS on agar gel 
electrophoresis and for prenatal screening samples testing for AS or SS. [62] Targeted screening 
of high risk individuals (family members of individuals identified with sickle cell disease or trait 
at the screening camps) was completed at the IGMC Hospital in Nagpur using HPLC.  
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4.1.2 Genotype Results & Counseling 
Individuals who were identified through screening to have an abnormal genotype were given 
identification cards with their name, age, date of birth, village, and genotype (AS/SS).  
Informational booklets were distributed that contained information about sickle cell disease and 
trait, inheritance patterns, disease-related issues and premarital counseling. The abnormal 
genotype cards were distributed by the counselor, who provided genetic counseling and gave 
additional information and answered questions. Subjects with SS disease were also referred to 
the onsite clinician, who collected relevant medical history and provided a medical examination. 
Patients were referred to comprehensive sickle cell clinic for follow up.  
4.1.3 Social Classifications 
Articles 341 and 342 of the Constitution of India provide statewide lists of communities 
classified as Scheduled Castes and Scheduled Tribes. Scheduled castes (SC) were historically 
known as the Untouchables and in the past occupied the lowest status in Indian society. The 
Scheduled Tribe (ST) populations are aboriginal people known as Adivasis. [63, 64] Other 
Backward Classes (OBC) are defined in the Indian Constitution as “socially and educationally 
backward classes” that fall outside the definition of ST and SC. [65] The relative proportion of 
these social groups in the State of Maharashtra are 10% (SC), 9% (ST) and 19% (OBC).[11] 
Within the SC, ST, and OBC there are different ethnic groups that have been identified 
and classified. The Scheduled Castes and Scheduled Tribes Orders (Amendment) Act, of 1976 
classifies the various sub-groups in the SC and ST populations. [65] From this list, the SC and 
ST populations screened were separated into six and 10 groups respectively, as listed below:  
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Scheduled Caste-(150 sub-groups within 59 groups) 
Group 1: Bhangi, Chambhar, Mehtar 
Group 2: Basori, Burad 
Group 3: Mang, Matang 
Group 4: Bauddha (Mahar) 
Group 5: Balai 
Group 6: Khatik 
Scheduled Tribe(184 sub-groups  within 47 groups) 
Group 1: Gond, Gowari, Mannewar, 
Madiya, Mana 
Group 2: Kawar, Ratha 
Group 3: Adivasi 
Group 4: Bhilala, Bhill 
Group 5: Halba 
Group 6: Kolam 
Group 7: Korku 
Group 8: Thakur 
Group 9: Pardhan 
Group 10: Dhangar 
 
The National Commission for Backward Classes Act of 1993 identifies all the different 
sub-groups within the OBC population in every state of India. [66] 
Other Backward Classes(261 groups) 
 
Group 1: Bari 
Group 2: Jangum 
Group 3: Koli 
Group 4: Koshti, Padmashali 
Group 5: Kumbhar 
Group 6: Kunbi 
Group 7: Kasar 
Group 8: Navi 
Group 9: Dhobi 
Group 10: Bhawsar 
Group 11: Devang, Sali 
Group 12: Shimpi 
Group 13: Sonar 
Group 14: Sutar 
Group 15: Warti 
Group 16: Wanjari 
Group 17: Sahu, Shahu, Teli 
Group 18: Mali, Vanmali 
Group 19: Yadav 
Group 20: Kochi 
Group 21: Gondhali 
Group 22: Thakur (Thakkar) 
 
 
Group 23: Kahar, Kirat 
Group 24: Pawar, Powar, 
Bhoyar 
Group 25: Kalar 
Group 26: Lingayat 
Group 27: Rangari 
Group 28: Raut 
Group 29: Wani 
Group 30: Puri 
Group 31: Pahadi 
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4.2 CLINICAL PHENOTYPE 
Subjects for the study were recruited from the pediatric comprehensive sickle cell program at the 
Government Medical College (GMC) in Nagpur, Maharashtra. Patients have been followed at 
this center by a single physician (DJ) for over 20 years.  They were enrolled in this prospective 
study of sickle cell phenotype from January 1, 2008, to May 31, 2012. Newborn screening 
(NBS) was instituted in 2010, and patients detected through NBS were excluded from this 
analysis. At the time of registration, the diagnosis of SCD was confirmed by standard procedures 
(cellulose acetate hemoglobin electrophoresis/high performance liquid chromatography) in all 
subjects. The study was approved by the institutional review board, GMC Nagpur, and written 
informed consent was obtained from all the patients and/or their parents at enrollment. 
Individuals lost to follow-up were excluded from analysis. Patients were started on Hydroxyurea 
(HU) therapy, if they were considered to have a severe phenotype as described in the MSH 
study. [67] Individuals already on HU therapy at study initiation were excluded, and data were 
excluded at initiation of HU therapy for patients who started HU during the study and only 
events before initiation of HU were included. Only events for which the patient was treated in 
the GMC hospital for medical care were used in the analysis.  
4.2.1 Laboratory Diagnosis 
The GMC of Nagpur determined the hemoglobin genotype by hemoglobin electrophoresis (Bio-
Rad)/ High Performance Liquid Chromatography (Hercules, CA, USA). [62] For those 
individuals who had received a blood transfusion prior to diagnosis a repeat confirmatory testing 
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was performed after three months. Complete blood count was performed using an auto-analyzer 
and reticulocyte count was performed with brilliant cresyl blue staining at the GMC.  
4.2.2 Data Collection 
These patients were followed up with regularly at the comprehensive sickle cell clinic with all 
relevant clinical and laboratory data documented in detailed case report forms. Patients were 
advised to follow up on a monthly basis or as symptoms presented. Patients included in this 
study received treatment and care, including for acute events, at the GMC, Nagpur. All children 
age less than five years were offered penicillin prophylaxis. Starting in 2009, the State 
Government of Maharashtra offered polysaccharide pneumococcal vaccination and Haemophilus 
influenzae type B vaccination free of charge to all patients. Since 2009 all patients between the 
ages of two and five were offered pneumococcal vaccination. Haemophilus influenzae type B, 
Typhoid, and Hepatitis B vaccines were given as per recommendations of Indian Academy of 
Pediatrics. [68]  
Demographic information about the family was recorded at the initial visit after 
diagnosis. Clinical records of these patients are available from the time of registration at the 
sickle cell clinic till the last available follow-up. Data for this study evaluated clinical events 
from January 1, 2008 to May 30, 2012, or until the last available follow-up within this time 
frame. 
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4.2.3 Definition of Events 
Only events for which the patient presented to the hospital for medical care were recorded and 
used for analysis. The event definitions were as follows: a painful event/crisis was defined as 
pain in the extremities, back, abdomen, chest, or head for which no other explanation could be 
found. Severe anemia was defined as a hemoglobin level less than 5g/dl. Sequestration crisis was 
defined as a decrease in the hemoglobin or hematocrit level of at least 20% from baseline 
accompanied by an increase in palpated spleen size of at least 2 cm from baseline. A febrile 
episode was defined as a hospitalization with fever (≥ 101º Fahrenheit). Confirmatory malarial 
diagnosis was defined as an identification of malaria parasite in a peripheral blood smear. 
Meningitis was defined as abnormal cerebrospinal fluid (CSF) findings and a positive CSF 
culture. Acute chest syndrome was defined by the following three symptoms: fever, tachypnea, 
and observation of new pulmonary infiltrates on x-ray. Stroke or a cerebrovascular accident 
(CVA) was defined as an acute neurologic syndrome secondary to the occlusion of an artery or 
to hemorrhage with resultant neurologic symptoms and signs.  
4.2.4 Statistical Analysis 
For assessing demographic information, frequency and percentage were computed for 
categorical data. For continuous data the median was computed, data categorized into 
meaningful groups and the frequencies computed within each group. For clinical data each visit 
with a certain condition was counted to assess its overall frequency. Furthermore the number of 
patients who had the specific condition at least once during the study period as well as the range 
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of occurrences of the condition within a person across the study population was compiled. 
Descriptive statistical analysis was carried out using SAS software 9.3 (Cary, NC, USA).  
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5.0  RESULTS 
5.1 POPULATION SCREENING 
Through both community screening and subsequent target screening of high-risk individuals a 
total of 35,636 individuals was screened, of whom 5,437 were found to have sickle cell trait 
(SCT) and 1,010 were identified with sickle cell disease (Table 2). A total of 16,832 individuals 
were screened in the community and targeted high-risk screening of 18,804 individuals was 
carried out at the IGMC Hospital. Sickle cell trait was identified in 1590 individuals and sickle 
cell disease was identified in 27 patients through the screening camps. The targeted hospital-
based screening of high-risk individuals identified 3,847 individuals with SCT and 983 
individuals with SCD.  
Table 2. Totals for all groups (Community wide screenings + High Risk Targeted screenings) 
 Total AA AS SS 
 N N N N 
SC-Camps 4399 3824 565 10 
SC-Hospital 10380 6930 2744 706 
ST- Camps 7430 6559 855 16 
ST-Hospital 2624 2047 460 117 
OBC-Camps 5003 4832 170 1 
OBC-Hospital 5800 4997 643 160 
Total 35636 29189 5437 1010 
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Community wide screening revealed a sickle cell trait (SCT) prevalence of 13% among 
the SC population, (Table 3), 12% in the ST population (Table 4), and 3.4% in the OBC (Table 
5) population.  
Within the Scheduled Caste population the sickle cell mutation was most prevalent in the 
Mahars. In the Scheduled Tribe population, the group consisting of the Gond, Gowari, 
Mannewar, Madiya, and Mana had the most number of individuals identified. Within the Other 
Backward Classes group, the Kunbi and Teli groups had the highest number of individuals 
identified with the βs gene mutation.  
Table 3. Scheduled Caste (SC) Community Wide Screening 
 Total AA AS SS 
  N (%) N (%) N (%) 
1 172 168 97.7 4 2.33 0 0 
2 1 1 100 0 0 0 0 
3 78 69 88.5 9 11.54 0 0 
4 4058 3507 86.4 541 13.33 10 0.25 
5 68 57 83.8 11 16.18 0 0 
6 22 22 100 0 0 0 0 
Total 4399 3824 86.93 565 12.84 10 0.25 
1: Bhangi, Chambhar, Mehtar, 2: Basori, Burad, 3: Mang, Matang, 4: Bauddha (Mahar), 5: Balai, 6: Khatik 
Sickle Cell Trait Prevalence among the Scheduled Caste Population = 13% 
 
Table 4. Scheduled Tribe (ST) Community Wide Screening 
 Total AA AS SS 
  N (%) N (%) N (%) 
1 5992 5227 87.23 754 12.58 11 0.18 
2 28 26 92.86 2 7.14 0 0 
3 71 64 90.14 6 8.45 1 1.41 
4 73 62 84.93 11 15.07 0 0 
5 216 216 100 0 0 0 0 
6 69 64 92.75 5 7.25 0 0 
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7 883 803 90.94 76 8.61 4 0.45 
8 2 2 100 0 0 0 0 
9 0 0 0 0 0 0 0 
10 96 95 98.96 1 1.04 0 0 
Total 7430 6559 88.28 855 11.51 16 0.22 
1: Gond, Gowari, Mannewar, Madiya, Mana, 2: Kawar, Ratha, 3: Adivasi, 4: Bhilala, Bhill, 5: Halba, 6: Kolam, 7: Korku, 8: Thakur, 9: Pardhan, 
10: Dhangar 
Sickle Cell Trait Prevalence among the Scheduled Tribe Population = 12% 
 
Table 5. Other backward classes (OBC) Community Wide Screening 
 Total AA AS SS 
  N (%) N (%) N (%) 
1 14 13 92.86 1 7.14 0 0 
2 2 2 100 0 0 0 0 
3 23 23 100 0 0 0 0 
4 96 92 95.83 4 4.17 0 0 
5 45 43 95.56 2 4.44 0 0 
6 2043 1953 95.59 89 4.36 1 0.05 
7 12 12 100 0 0 0 0 
8 105 103 98.10 2 1.90 0 0 
9 129 126 97.67 3 2.33 0 0 
10 14 14 100 0 0 0 0 
11 17 17 100 0 0 0 0 
12 67 67 100 0 0 0 0 
13 174 172 98.85 2 1.15 0 0 
14 119 114 95.80 5 4.20 0 0 
15 14 14 100 0 0 0 0 
16 20 20 100 0 0 0 0 
17 1105 1073 97.10 32 2.90 0 0 
18 502 486 96.81 16 3.19 0 0 
19 60 60 100 0 0 0 0 
20 6 6 100 0 0 0 0 
21 7 7 100 0 0 0 0 
22 100 92 92.00 8 8.00 0 0 
Table 4 continued 
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23 11 10 90.91 1 9.09 0 0 
24 156 155 99.36 1 0.64 0 0 
25 158 154 97.47 4 2.53 0 0 
26 4 4 100 0 0 0 0 
Total 5003 4832 96.58 170 3.40 1 0.02 
1: Bari, 2: Jangum, 3: Koli, 4: Koshti, Padmashali, 5: Kumbhar, 6: Kunbi, 7: Kasar, 8: Navi, 9: Dhobi, 10: Bhawsar, 11: Devang, Sali, 12: 
Shimpi, 13: Sonar, 14: Sutar, 15: Warti, 16: Wanjari,  17: Sahu, Shahu, Teli, 18: Mali, Vanmali, 19: Yadav, 20: Kochi, 21: Gondhali, 22: Thakur 
(Thakkar), 23: Kahar, Kirat, 24: Pawar, Powar, Bhoyar, 25: Kalar, 26: Lingayat 
 
Sickle Cell Trait Prevalence among the Other Backward Classes = 3.4% 
5.2 CLINICAL PHENOTYPE 
A total of 726 patients were followed in the comprehensive clinic; data of 22 were excluded due 
to death, data of 33 were excluded due to lost to follow up and the data of 25 individuals was 
excluded at the time they were started on HU. Thirty-nine of these patients were followed for 
less than six months. Eighty-three percent of the patients have homozygous sickle cell disease 
(SS), and fifteen percent have Sβ+ Thalassemia (Sβ+) or Sβ0 Thalassemia (Sβ0). Three hundred 
and three (42%) patients were female, and 423 patients (58%) were male. Twenty-seven percent 
of patients were identified under the age of two years, 36% were diagnosed between two and 
give years of age and 36% were diagnosed after the age of five. There were a total of 1798.4 
patient years of observation and 3527 hospital visits recorded. 
5.2.1 Population Demographics 
The majority of families belong to the lower socio-economic class with a monthly income of 
over 86% of families being less than a $100. Forty-nine percent of fathers and 55% of mothers 
Table 5 continued 
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have an education level that is less than or equivalent to a middle school level. Table 6 illustrates 
the caste distribution within the patient cohort. In this cohort, the majority of patients are part of 
the SC or "non-tribal” population.  
Table 6. Ethnic Group Distribution in the Study Population 
 
 
 
 
 
 
5.2.2 Clinical Events 
Table 7 illustrates the clinical events observed in the patient cohort. The rates of painful crisis 
and fever were the most common sickle cell related events in homozygous SCD (SS) and 
hemoglobin Sβ+/Sβ0 patients (overall incidence of 55.88 and 49.27 cases per 100 person-years, 
respectively). Severe anemia was observed with an incidence of 6.28 cases per 100 person-years 
and malaria with an incidence of 0.72 cases per 100 person-years. Sequestration crisis and acute 
chest syndrome were observed with an overall incidence of 1.56 and 0.83 cases per 100 person-
years respectively. The incidence rate for stroke and meningitis was 0.28 and 0.11 per 100 
person years, respectively.  
 
 
 
 
Ethnic Group # of Individuals 
Scheduled Caste 481 
Scheduled Tribe 72 
Other Backward Class 123 
Nomadic Tribe 2 
Other 
           
           
           
30 
 
 
 
Unknown 17 
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Table 7. Incidence of Clinical Events per 100 person years 
Clinical Event 
Nagpur cohort per 100 
person years 
(1771 person years 
observation) 
CSSCD newborn cohort 
per 100 person years          
(1851 person years 
observation) 
Painful Crisis 66.52 32.4 
Fever 58.32 39.30 
Severe Anemia 7.11 4.3 
Sequestration Crisis 1.64 3.63 
Acute Chest 
 
1.13 24.5 
Malaria 0.90 None reported 
Death 1.24 1.1 
 
5.2.3 Mortality 
Over the four and a half year time period, 22 patients (3.0% or 1.22 cases per 100 person- years) 
died. The causes of death in this cohort (Table 8) include: infection, splenic sequestration, severe 
anemia presenting with hypoxic ischemic encephalopathy, and stroke. Thirty-two percent of the 
recorded deaths are due to unknown causes or deaths that occurred at home for which no 
causative information is available. 
Table 8. Causes of Mortality by Age Distribution 
 Infection Sequestration Anemia Stroke Cardiac Failure 
Under 5 years 2 1 1 3 0 
5-7 years 0 2 1 0 0 
8-10 years 0 0 0 0 0 
> 10 years 2 1 1 0 1 
Total 4 4 3 3 1 
Deaths at Home, Cause Unknown: 7 
Total Deaths: 22 
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6.0  DISCUSSION 
6.1 POPULATION SCREENING 
Our study for the first time describes the results of community based screening for the 
prevalence of the βs gene in different SC groups within Central India. The practice of endogamy 
in India provides the rationale for the screening of individual populations to better understand the 
distribution of the βs gene and guide counseling and awareness programs.  
Large scale screening as described in this study has been the foundation for regional 
disease control programs. [5] While mass screening has provided detailed descriptions for the ST 
population in previous studies, such detailed descriptions are as yet unavailable for the SC and 
OBC populations. [1, 3, 4, 6-8, 10, 69-71] 
Published studies to date have not distinguished between community-based screening of 
the general population and secondary screening of family members as a result of detection of a 
sickle cell mutation in an index case. Secondary screening is likely to reveal a higher prevalence 
of the βs gene than in the general population. The multiplicity of ethnic groups and overlapping 
terminology restricts the utility of prevalence studies. This study addresses these limitations by 
using standardized terminology as defined by the Census of India [11] and government 
regulations as well as by grouping ethnic groups that are closely related, have social interactions, 
and practice inter-marriage to determine the prevalence rates of the βs gene.  
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Description of the prevalence of SCT in individual caste groups has immediate practical 
implications. As seen in the study, using community based screening data to target high-risk 
individuals has identified a large number of individuals with both sickle cell trait and disease. In 
lower resource countries, population screening and secondary target screening can identify 
individuals who may not have otherwise sought care. Identifying these individuals can lead to 
referrals to comprehensive care clinic to receive the appropriate medicine and follow-up .  
 The implications for these mass screenings extend beyond identifying carriers of the βs 
gene mutation.  Emerging data on the potential contribution of sickle cell trait to catastrophic 
clinical events following extreme physical exertion, such as in military training or professional 
sporting events, suggest the need for individual awareness of sickle cell trait status. Premarital 
counseling can be targeted and tailored to the specific groups in which there is a high βs mutation 
prevalence. Population-wide screenings can help target specific groups and populations in need 
of education to raise awareness levels about screening, health implications, treatment, 
management and pre-marital counseling.  
Population screening studies help better define the magnitude of a public health problem. 
The Mahars, the largest most widespread Scheduled Caste group in India, live in large numbers 
in an area extending from the Arabian Sea coast in the west to the Bastar plateau in the east, and 
are a varied group considered to have originated by admixture between the autochthons of the 
eastern region of Central India and the Proto-Australoid element from the south and constitute 
around 9% of the total population of Maharashtra. [71, 72] The SC and ST groups with a 
combined population of 18 million and a trait prevalence of 13% and 12% respectively account 
for 2.5 million carriers (1.4 million SC & 1.1 million ST) of sickle cell trait in the state of 
Maharashtra alone. [11] Additionally, the Other Backward Classes comprising 52% of the state’s 
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population account for 1.9 million carries of sickle cell trait in the state.  These groups also spill 
over to neighboring states of Gujarat, Madhya Pradesh and Chattisgarh representing an even 
larger burden of βs gene. In comparison, the African American population accounts for 40 
million individuals in the United States and with a SCT prevalence of 8%, represent over three 
million carriers of the βs gene. [73, 74]  
6.2 CLINICAL PHENOTYPE 
These findings represent the first report of a large prospectively phenotyped cohort of patients 
with SCD in India. The clinical picture in the ethnic groups that are present in large numbers in 
these areas are described and as such must be interpreted as being descriptive of phenotype in 
these groups only. While various ethnic groups are represented in the patient population, the SC 
population accounts for a large majority of patients. Vaso-occlusive crisis (VOC) and fever 
followed by severe anemia are the most common initial presentations and were the leading 
causes of hospitalizations. The rates of pain crisis and fever in this cohort are higher when 
compared to the data published from the Cooperative Study of Sickle Cell Disease (CSSCD). 
[13]  
Severe anemia was also more commonly observed than what was reported in CSSCD. 
[13] The cause of a high rate of severe anemia in patients with SCD in this cohort is unknown. 
[13] Malaria is a significant co-morbidity in this Indian population. It is possible that 
malnutrition, infections and malaria may have contributed to the presentation of severe anemia. 
Further investigation, however, is indicated to better understand this common co-morbidity. It is 
intriguing that the rate of acute chest syndrome is strikingly lower in this population. This is 
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particularly surprising in light of the high incidence of pneumonia in the country, with India 
alone being responsible for over a quarter of the deaths in the world from pneumonia in children 
under the age of five years. [75, 76] The lower frequency of splenic sequestration is also 
intriguing. It is possible that this may be reflective of lack of access to care and that splenic 
sequestration may represent some of the deaths at home with no known cause.  
The mortality rate observed in this Indian population (1.24 cases per 100 person-years) is 
comparable to the observed rate seen in the CSSCD (1.1 cases per 100 person-years). [13] The 
leading causes of death in this cohort include: infection, splenic sequestration, severe anemia 
presenting with hypoxic ischemic encephalopathy, stroke and cardiac failure. That nearly one-
third of the recorded deaths occurred at home, due to unknown causes may also be reflective of 
barriers to care for this population. 
The high rate of VOC, fever, septic arthritis and unique co-morbidities such as severe 
anemia and malaria and the high rates of mortality, all suggest that the phenotype of SCD as 
observed in Nagpur is not milder than that observed in CSSCD. This is in contrast with previous 
published reports suggesting a milder phenotype of SCD in India. [12] However; these reports 
were based on cross-sectional studies of a relatively small number of patients. The current 
analysis underscores the need for careful study of the clinical course of large cohorts of patients 
prospectively to accurately describe phenotype. That the majority of patients are from low 
socioeconomic populations with barriers to care is supportive of this possibility.  
Environmental and nutritional factors may also contribute to high rate of febrile episodes 
especially in a low resource country. These along with endemicity of malaria may further 
contribute to high morbidity and possibly premature mortality in patients with SCD in this 
region. These findings are also in keeping with our prior retrospective observations. [77] They 
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are also concordant with cross-sectional observations suggesting high rates of VOC events, 
infections, organ damage and premature mortality from eastern India. [69] These data provide a 
compelling rationale for large prospective studies in different ethnic groups in India to determine 
the contribution of environmental, biological and health systems influences to variation in 
clinical phenotype.   
Median age of diagnosis was four years. This has the potential effect of excluding both 
those who succumbed to pneumococcal sepsis in early childhood as well as those with mild 
manifestations who may never present for clinical care at a tertiary care hospital. Further, we 
excluded patients who were already on HU at the commencement of the study and censored data 
at initiation of HU on those enrolled in the study in order to describe phenotype modified by HU. 
Thus, patients with severe phenotype who were started on HU therapy are likely to be under 
represented in this analysis. These data do, however, indicate that the clinical manifestations of 
sickle cell disease in India are no less severe than that observed among those who seek care for 
this disease in the United States. 
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7.0  CONCLUSION 
We provide for the first time detailed prevalence data of the βs gene among SC and OBC ethnic 
groups in Maharashtra in Central India. These population screening programs have uncovered 
previously undiagnosed cases, provided detailed information for population based disease 
counseling, prevention programs and comprehensive care programs. Over 5,000 individuals were 
identified with SCT and more than 1,000 individuals were identified with SCD through 
community-based and target high-risk screening. The population screening study shows how 
community-based screening can identify individuals who may not have otherwise sought care 
and guide individuals to available comprehensive care centers. The screening also helped 
identify specific sub-groups within the SC, ST, and OBC population that have higher prevalence 
rates of the βs gene. With a SCT prevalence of 13%, 12% and 3.4% in the SC, ST, and OBC 
populations respectively, an estimated 4.4 million individuals in the state of Maharashtra alone 
are expected to have SCT. Similar community-based screening programs need to be initiated 
throughout regions of India that have a high prevalence of SC, ST, and OBC populations to 
determine the true prevalence of the βs gene in India. 
Additionally, we present the first evidence suggesting that SCD may not have milder 
manifestations in India and underscore the need for detailed studies of phenotype that can form 
the basis of public health interventions as well as mechanistic studies of genetic modifiers of 
clinical phenotype. Our data shows that the rates of painful crises and fever the two most 
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common clinical manifestations were observed at higher rates than individuals in the African 
American population in the United States. Other unique co-morbidities such as severe anemia 
and malaria were identified that can help direct future research studies to determine exactly how 
this co-morbidities affect the course of disease. A limitation of this study is that patients were 
diagnosed when they presented with clinical manifestations of SCD rather on newborn 
screening. Thus this cohort is not strictly comparable with the CSSCD newborn cohort. 
The observation of a severe of phenotype of SCD in India however, has many 
implications. It makes the case for interventions such as newborn screening and comprehensive 
care and disease modifying therapy such as HU. The magnitudes of both the at-risk population 
and the burden of morbidity also suggest the need for public policy to address this major public 
health problem. This study, by clearly delineating phenotype can serve as the basis for studies of 
genetic modifiers of phenotype in this population.  
The burden of SCD in India has not been well documented or studied thus far. These two 
studies are of high public health significance and important for the planning of health care 
delivery services. The study has implications for the need for comprehensive clinical care and 
further population based prevalence studies in other regions of India to truly understand the 
impact and burden of SCD in underserved populations. 
This thesis reflects the work performed and the author wishes to add a comment.  
Comment: Conducting the research for these projects was one of the most unique and greatest 
learning experiences that I have ever had. I had an opportunity that most students never have the 
chance to experience and had the honor of meeting and working with four different research 
groups throughout India on my journey to learn about how Sickle Cell Disease affects 
individuals in India. I had the chance to attend screening camps and meet individuals from the 
various villages and every single individual I met was willing to help me learn and teach me all 
that they knew. Growing up I have made numerous trips to India to visit family members but this 
project was an eye opening experience and I learned more in my two trips to India for my thesis 
compared to all the previous trips that I have made before. The sickle cell patients and families 
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were so friendly, open and willing to talk to me so that I can learn about their experiences. While 
I hope this work truly provides a framework for future research pertaining to SCD in India it has 
helped me not only learn about the topic but also about myself and was a phenomenal 
experience.  
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